Company intelligence / Profile preview
Cloudbreak Pharma
Irvine, California, USAcloudbreakpharma.com ↗
- Ownership
- Public · 2592.HK
- Development stage
- Phase 3
01
Overview
Cloudbreak Pharma is advancing its lead candidate CBT-001 in Phase 3 multi-regional clinical trials for pterygium treatment. The company has completed a Phase 1/2 trial for CBT-009 for juvenile myopia and submitted an IND application to the FDA in July 2024. Two other candidates (CBT-006 and CBT-004) are in Phase 2 trials, with four additional candidates in pre-clinical development.
- Therapeutic areas
- Ophthalmology
- Modalities
- Small molecule drugsChemical drugsAntibody drug conjugate (ADC)
- Industry
- Biotech
02
Drug pipeline
12 assets11 more assets in the full pipeline.
03
Partnerships
Santen Pharmaceutical Co., Ltd. (TYO:4536) - August 2024 licensing agreement for CBT-001Grand Pharma (00512.HK) - April 2020 commercialization licensing arrangement for CBT-001
Beyond the preview
Go deeper on Cloudbreak Pharma.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Cloudbreak Pharma.